Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-08-26Clinical Trial Update: Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer [Phase 2]
This update reports results from a Phase 2 study evaluating PD-L1 positive non-small cell lung cancer treated with immunotherapy as monother…
-
CLINICAL_TRIALS trial_result · 2025-08-26Clinical Trial Update: Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003) [Phase 3]
A Phase 3 trial comparing the pembrolizumab/vibostolimab coformulation MK-7684A with pembrolizumab monotherapy in PD-L1–positive metastatic …
-
CLINICAL_TRIALS trial_result · 2025-08-22Clinical Trial Update: Dexamethasone Effects in Patients With Refractory Non-Small Cell Lung Cancer Using FLT Positron Emission Tomography [NA]
Clinical trial update reporting results of dexamethasone effects in patients with refractory non-small cell lung cancer, assessed using FLT …
-
CLINICAL_TRIALS trial_result · 2025-08-21Clinical Trial Update: A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung [Phase 1]
Phase I/Ib study evaluating the MEK1/2 inhibitor binimetinib (MEK162) in combination with carboplatin and pemetrexed in patients with non-sq…
-
CLINICAL_TRIALS trial_result · 2025-08-20Clinical Trial Update: Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial update reports results from evaluating the combination of sirolimus and auranofin in patients with advanced…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-08-20Clinical Trial Update: Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) [Phase 1, Phase 2]
Phase 1/2 trial results for GLIMMER-01, a bi-sialidase fusion protein from Palleon, tested across multiple solid tumors with results posted …
-
CLINICAL_TRIALS trial_result · 2025-08-20Clinical Trial Update: A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors [Phase 1]
This Phase 1 trial assesses safety, tolerability, and preliminary efficacy of lomvastomig, a PD-1/TIM-3 bispecific antibody, in adults with …
-
CLINICAL_TRIALS trial_result · 2025-08-20Clinical Trial Update: Feasibility of Intratumoral Washing Fluid for Detecting EGFR Mutations in Lung Cancer [NA]
A completed study assessing the feasibility of using intratumoral washing fluid to detect EGFR mutations in non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2025-08-19Clinical Trial Update: A Trial of AK104 Plus Anlotinib in NSCLC [Phase 1, Phase 2]
Clinical trial update indicating completion of Phase 1 and Phase 2 studies of AK104 plus anlotinib in non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2025-08-19Clinical Trial Update: A Study to Examine Biomarkers From Lung and Blood Samples in Participants With Suspected Lung Cancer
A completed study from Janssen examining biomarkers in lung and blood samples from participants with suspected non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2025-08-19Clinical Trial Update: HS-IT101 Injection for Advanced NSCLC [Phase 1]
Phase 1 clinical trial update for HS-IT101 Injection in advanced non-small cell lung cancer, with the study listed as not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2025-08-17Clinical Trial Update: Pemetrexed/Platinum With or Without Bevacizumab in Brain Metastases From Patients With EGFR/ALK Negative Non-Squamous Non-small Cell Lung Cancer [Phase 3]
A Phase 3 trial evaluating pemetrexed/platinum with or without bevacizumab in patients with EGFR/ALK-negative non-squamous non-small cell lu…
-
CLINICAL_TRIALS trial_result · 2025-08-17Clinical Trial Update: Comparison of Longer-term (5 Year+) Outcomes (Survival) of Smokers, Ex-smokers, Never Smoker and Quitters
Clinical trial update reporting longer-term (5+ year) survival outcomes. It compares smokers, ex-smokers, never smokers, and quitters in pat…
-
CLINICAL_TRIALS trial_result · 2025-08-17Clinical Trial Update: Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) [Phase 3]
A Phase 3 trial MK-7339-012/KEYLYNK-012 evaluating pembrolizumab with concurrent chemoradiation followed by pembrolizumab with or without ol…
-
CLINICAL_TRIALS trial_result · 2025-08-17Clinical Trial Update: Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology [NA]
A completed clinical trial evaluating whether therapeutic patient education can reduce the toxicity associated with immune checkpoint inhibi…
-
CLINICAL_TRIALS trial_result · 2025-08-15Clinical Trial Update: Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies [Phase 1]
Phase 1 dose-escalation and expansion study of intratumoral mRNA-2752 in advanced malignancies has completed, with expansion cohorts in seve…
-
CLINICAL_TRIALS trial_result · 2025-08-15Clinical Trial Update: 1st Line Durvalumab in PS 2 NSCLC Patients [Phase 2]
Clinical trial update describing a Phase 2 study of first-line durvalumab in performance status 2 non-small cell lung cancer patients (stage…
-
CLINICAL_TRIALS trial_result · 2025-08-14Clinical Trial Update: The Watch the Spot Trial [NA]
The Watch the Spot Trial (NCT02623712), sponsored by Kaiser Permanente, has completed its study on solitary pulmonary nodules and related co…
-
CLINICAL_TRIALS trial_result · 2025-08-14Clinical Trial Update: Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors [Phase 1]
A Phase 1 trial evaluating tovorafenib (DAY101) alone or with pimasertib for melanoma and other solid tumors has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-08-12Clinical Trial Update: A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation [Phase 1, Phase 2]
A Phase 1/2 study evaluating GFH925 in combination with cetuximab for previously untreated advanced non-small cell lung cancer with a KRAS G…
-
CLINICAL_TRIALS trial_result · 2025-08-11Clinical Trial Update: Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer [Phase 1]
Phase 1 safety study evaluating enoblituzumab (MGA271) in combination with pembrolizumab or MGA012 in patients with refractory cancers. Resu…
-
CLINICAL_TRIALS trial_result · 2025-08-11Clinical Trial Update: D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC [Phase 2, Phase 3]
A head-to-head Phase 2/Phase 3 trial compares D-0316 to icotinib in locally advanced or metastatic non-small cell lung cancer with EGFR-sens…
-
CLINICAL_TRIALS trial_result · 2025-08-11Clinical Trial Update: A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours [Phase 1, Phase 2]
Cancer Research UK reported an ongoing Phase 1/2a trial of HMBD-001 in HER3-positive solid tumors; the study is currently Active Not Recruit…
-
CLINICAL_TRIALS trial_result · 2025-08-08Clinical Trial Update: Survival Efficacy of Combined Radiotherapy and Immunotherapy in Patients With Metastatic Non-small Cell Lung Carcinoma
This update reports on survival outcomes for a combination of radiotherapy and immunotherapy in metastatic non-small cell lung cancer, with …
-
CLINICAL_TRIALS trial_result · 2025-08-08Clinical Trial Update: Study to Evaluate CCS1477 in Advanced Tumours [Phase 1, Phase 2]
A Phase 1/2 study of CCS1477 has completed, evaluating it in metastatic castration-resistant prostate cancer and metastatic breast cancer, w…